Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Roche Holding AG Basel American Depositary Shares
(OP:
RHHBY
)
29.83
+0.57 (+1.95%)
Streaming Delayed Price
Updated: 3:59 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Roche Holding AG Basel American Depositary Shares
< Previous
1
2
3
4
5
Next >
Majority of Newborn Babies With Spinal Muscular Atrophy (SMA) Treated With Genentech’s Evrysdi Able to Sit Independently After 1 Year of Treatment
October 04, 2023
From
Genentech
Via
Business Wire
Genentech to Present New Key Clinical and Real-world Data at ECTRIMS-ACTRIMS 2023 Showcasing Strength of Long-term Outcomes in MS and NMOSD
October 02, 2023
From
Genentech
Via
Business Wire
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation
September 20, 2023
Via
Investor Brand Network
Exposures
Product Safety
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation
September 20, 2023
EQNX::TICKER_START (NASDAQ:GNPX),(OTCQX:RHHBY),(NASDAQ:JAZZ),(NASDAQ:ALXO),(NASDAQ:ACHL) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
Global Dry Eye Syndrome Treatment Market Expected to Reach $11.26 Billion By 2030
September 08, 2023
EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:ALC),(NYSE:BLCO),(NYSE:JNJ),(OTCQX:RHHBY) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
COVID-19
FDA Accepts Application for Genentech’s Crovalimab for the Treatment of PNH, a Rare Life-Threatening Blood Condition
September 06, 2023
From
Genentech
Via
Business Wire
Genentech’s Alecensa Delivers Unprecedented Phase III Results for People With ALK-Positive Early-Stage Lung Cancer
September 01, 2023
From
Genentech
Via
Business Wire
Genentech Provides Update on Phase III SKYSCRAPER-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer
August 23, 2023
From
Genentech
Via
Business Wire
New Clinical and Real-World Data for Genentech’s Vabysmo at ASRS Reveal Improved Outcomes for People With Two Leading Causes of Vision Loss
July 20, 2023
From
Genentech
Via
Business Wire
Nvidia Invested $50 million into This AI Drug Discovery Biotech
July 17, 2023
Clinical-stage biotechnology company Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) saw its stock double on the announcement of a $50 million investment from
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Positive Phase III Results for Genentech’s Ocrevus (ocrelizumab) Twice a Year, 10-Minute Subcutaneous Injection in Patients With Multiple Sclerosis
July 13, 2023
From
Genentech
Via
Business Wire
Four-Year Follow-Up Data for Genentech’s Evrysdi Show Continued Increase in Number of Children With a Severe Form of Spinal Muscular Atrophy (SMA) Able to Sit, Stand and Walk
June 30, 2023
From
Genentech
Via
Business Wire
Agilent Technologies Stock: Ready to Rise off the Floor
June 21, 2023
Agilent Technologies Inc. (NYSE: A) stock is underperforming the market, trading down (19%) year-to-date. Agilent is a leading global provider.
Via
MarketBeat
FDA Approves Genentech’s Columvi, the First and Only Bispecific Antibody With a Fixed-Duration Treatment for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
June 15, 2023
From
Genentech
Via
Business Wire
New Data Show Genentech’s Subcutaneously Administered Crovalimab Achieved Disease Control and Was Well-Tolerated in People With Paroxysmal Nocturnal Hemoglobinuria (PNH)
June 09, 2023
From
Genentech
Via
Business Wire
Genentech’s BTK Inhibitor Fenebrutinib Significantly Reduced Brain Lesions in People With Relapsing Forms of Multiple Sclerosis
May 17, 2023
From
Genentech
Via
Business Wire
Sarepta Soars 31% As FDA Panel Backs Muscular Dystrophy Therapy
May 16, 2023
Sarepta Therapeutics soars 31% as FDA committee supports gene therapy for Duchenne muscular dystrophy. Analysts have a "moderate buy" rating on the stock.
Via
MarketBeat
Exposures
Product Safety
FDA Accepts Application for Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)
May 09, 2023
From
Genentech
Via
Business Wire
Regeneron Beats Q1 Views, But Stock Drops On Weak Eye Med Sales
May 05, 2023
Regeneron reported better-than-expected Q1 earnings and revenue, but its Eylea sales fell, losing ground to Roche's newly launched Vabysmo.
Via
MarketBeat
New Vabysmo Data Suggest Greater Retinal Drying Versus Aflibercept in Wet Age-Related Macular Degeneration and Diabetic Macular Edema
April 25, 2023
From
Genentech
Via
Business Wire
Genentech Announces Industry-Leading Brain Health Research Collaborations and Latest Data Across Neuroscience Medicines at AAN 2023 Annual Meeting
April 24, 2023
From
Genentech
Via
Business Wire
FDA Approves Genentech’s Polivy in Combination With R-CHP for People With Certain Types of Previously Untreated Diffuse Large B-cell Lymphoma
April 19, 2023
From
Genentech
Via
Business Wire
Genentech’s Tecentriq Plus Avastin Reduced the Risk of Cancer Returning in People With Certain Types of Adjuvant Liver Cancer in a Phase III Study
April 16, 2023
From
Genentech
Via
Business Wire
Genentech Data Highlights Strength of Ophthalmology Portfolio and Commitment to Advancing Eye Care at ARVO 2023
April 13, 2023
From
Genentech
Via
Business Wire
New Four-Year Data for Genentech’s Evrysdi Reinforce Long-Term Efficacy and Safety Profile in Some of the Most Severely Affected People With Types 2 and 3 Spinal Muscular Atrophy (SMA)
March 20, 2023
From
Genentech
Via
Business Wire
Biotech Sector Working Fast to Combat Alzheimer’s Disease Cases That are Set to Explode
March 15, 2023
FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 15, 2023 – USA News Group – According to a 2022 study of more than 6 million patients 65 and older, the risk factor for...
Via
FinancialNewsMedia
Exposures
COVID-19
FDA Advisory Committee Votes in Favor of the Clinical Benefit of Genentech's Polivy Combination for People With Previously Untreated Diffuse Large B-Cell Lymphoma
March 09, 2023
From
Genentech
Via
Business Wire
New Phase III Data Show Genentech’s Vabysmo Rapidly Improved Vision and Reduced Retinal Fluid in People With Retinal Vein Occlusion (RVO)
February 10, 2023
From
Genentech
Via
Business Wire
Genentech Announces Positive Data From Global Phase III Program for Crovalimab in PNH, a Rare, Life-Threatening Blood Condition
February 07, 2023
From
Genentech
Via
Business Wire
Genentech’s Tecentriq Plus Avastin Is the First Treatment Combination to Reduce the Risk of Cancer Returning in People With Certain Types of Early-Stage Liver Cancer in a Phase III Trial
January 19, 2023
From
Genentech
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.